[Clinical Picture] A polymorphous bullous dermatosis
A 50-year-old woman with an advanced high-grade serous ovarian cancer was admitted to the oncology department at Gustave Roussy Institute (Villejuif, France) in October 2016 because of large and painful supraclavicular erosions. Initially diagnosed as radiodermatitis, the erosions appeared 4 weeks after a localised palliative radiotherapy on a supraclavicular metastatic lymphadenopathy. Subsequently, erosions of the oral mucosa and widespread cutaneous lesions occurred in November, 2016. The patient was referred by her oncologist to our dermatology department at Henri Mondor Hospital (Cr éteil, France). (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Faustine Drahy, Claire Hotz, Nicolas Ortonne, Lisa Ghoufi, Sabine Grootenboer-Mignot, Christophe Massard, Marie-Pierre Perrin, Olivier Chosidow, Saskia Ingen-Housz-Oro Tags: Clinical Picture Source Type: research
[Policy Review] Defining a global research and policy agenda for betel quid and areca nut
Betel quid and areca nut are known risk factors for many oral and oesophageal cancers, and their use is highly prevalent in the Asia-Pacific region. Additionally, betel quid and areca nut are associated with health effects on the cardiovascular, nervous, gastrointestinal, metabolic, respiratory, and reproductive systems. Unlike tobacco, for which the WHO Framework Convention on Tobacco Control provides evidence-based policies for reducing tobacco use, no global policy exists for the control of betel quid and areca nut use. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Hedieh Mehrtash, Kalina Duncan, Mark Parascandola, Annette David, Ellen R Gritz, Prakash C Gupta, Ravi Mehrotra, Amer Siddiq Amer Nordin, Paul C Pearlman, Saman Warnakulasuriya, Chi-Pang Wen, Rosnah Binti Zain, Edward L Trimble Tags: Policy Review Source Type: research
[Policy Review] European position statement on lung cancer screening
Lung cancer screening with low-dose CT can save lives. This European Union (EU) position statement presents the available evidence and the major issues that need to be addressed to ensure the successful implementation of low-dose CT lung cancer screening in Europe. This statement identified specific actions required by the European lung cancer screening community to adopt before the implementation of low-dose CT lung cancer screening. This position statement recommends the following actions: a risk stratification approach should be used for future lung cancer low-dose CT programmes; that individuals who enter screening pro...
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Matthijs Oudkerk, Anand Devaraj, Rozemarijn Vliegenthart, Thomas Henzler, Helmut Prosch, Claus P Heussel, Gorka Bastarrika, Nicola Sverzellati, Mario Mascalchi, Stefan Delorme, David R Baldwin, Matthew E Callister, Nikolaus Becker, Marjolein A Heuvelmans, Tags: Policy Review Source Type: research
[Review] Radiotherapy in the setting of breast reconstruction: types, techniques, and timing
As the use of breast reconstruction and postmastectomy radiotherapy (PMRT) has increased over the past decade, the typical approach to integrating radiotherapy with breast reconstruction has provoked intense controversy in the management of breast cancer. PMRT can lead to an increased frequency of complications in the reconstructed breast. Conversely, the reconstructed breast can increase the complexity of radiotherapy delivery. How to minimise the frequency of complications without compromising oncological or cosmetic outcomes of the reconstructed breast is an important shared multidisciplinary goal for oncologists and th...
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Alice Y Ho, Zishuo I Hu, Babak J Mehrara, Edwin G Wilkins Tags: Review Source Type: research
[Review] De-novo and acquired resistance to immune checkpoint targeting
Use of immune checkpoint inhibitors targeting the programmed cell death protein-1/programmed cell death-ligand 1 and cytotoxic T lymphocyte-associated protein-4 axes has yielded impressive results in some clinical trials. However, only a subset of patients initially respond to these inhibitors, and increasing clinical evidence indicates that a substantial proportion of initial responders ultimately relapse with lethal, drug-resistant disease months or years later. Studies that have used massively parallel sequencing have shed light on the rich functional landscape of mutations that endow tumour cells with the ability to ev...
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Nicholas L Syn, Michele W L Teng, Tony S K Mok, Ross A Soo Tags: Review Source Type: research
[Review] An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report
Spinal metastases are becoming increasingly common because patients with metastatic disease are living longer. The close proximity of the spinal cord to the vertebral column limits many conventional therapeutic options that can otherwise be used to treat cancer. In response to this problem, an innovative multidisciplinary approach has been developed for the management of spinal metastases, leveraging the capabilities of image-guided stereotactic radiosurgery, separation surgery, vertebroplasty, and minimally invasive local ablative approaches. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Daniel E Spratt, Whitney H Beeler, Fabio Y de Moraes, Laurence D Rhines, Joseph J Gemmete, Neeraj Chaudhary, David B Shultz, Sean R Smith, Alejandro Berlin, Max Dahele, Ben J Slotman, Kelly C Younge, Mark Bilsky, Paul Park, Nicholas J Szerlip Tags: Review Source Type: research
[Cancer and Society] Island
A lot of mist can settle over the Solent, the straits that separate the Isle of Wight from the English mainland. On some days, you hear the passenger ferry before you see it; whirring and clanking, and the blast of the horn. The ship slowly assumes shape, shimmering and uncertain at first, and finally emerging from the fog. After it docks, the passengers stream out. Some are on bicycles, most are on foot. After a while, the ferry leaves again. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: Cancer and Society Source Type: research
[Cancer and Society] Make Blood Cancer Visible
Walking through Paternoster Square near London's St Paul's Cathedral during the month of September, you are greeted by an unusual and striking array of blood-red, three-dimensional sculptures of names standing vertically. This public installation is the launch of a campaign run by Janssen Oncology to raise awareness and education about blood cancer; to, in effect, make blood cancer visible. Janssen Oncology, in partnership with nine other blood cancer patient groups, conducted both a public survey and a survey of patients diagnosed with blood cancer to generate statistics about perceptions surrounding blood cancer. (Source...
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Anna Kennedy Tags: Cancer and Society Source Type: research
[Cancer and Society] Die young with me
In the refreshingly unconventional Die Young With Me, Rob Rufus has reinvigorated the cancer memoir genre. Readers discovering this book outside of the strictly categorised worlds of bookshops and libraries could be forgiven for thinking they had discovered a work of fiction, something akin to John Green's The Fault in our Stars. The first person narrative coupled with the high school setting and cast of teenage characters serve to further this fiction-like tone, as does the introductory storyline: boy meets girl, the outcast and the cheerleader. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Victoria Denny Tags: Cancer and Society Source Type: research
[Cancer and Society] The art of death
Edwidge Danticat's The Art of Death, Writing the Final Story is an intimate look at one woman's journey to make sense of death, including the recent loss of her mother to stage IV ovarian cancer. To understand death, the novelist turns to her innate comfort, the written word. Drawing on the great authors and their representations of death, she begins to make sense of the great loss she has seen in her life. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Caroline A Kinsey Tags: Cancer and Society Source Type: research
[Corrections] Correction to Lancet Oncol 2017; 18: 1555 –56
Bestvina CM and Vokes E. ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. Lancet Oncol 2017; 18: 1555 –56—In this Comment, the sixth sentence in the third paragraph should have read “Grade 3 or worse pulmonary toxicity occurred in 3% of patients treated with brigatinib.” This correction has been made as of Nov 29, 2017, and the printed version is correct. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2017; 18: 1493 –1501
Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18: 1493 –1501—In this Article (published online on Oct 4, 2017), the Interpretation in the Summary should have read “The primary endpoint of overall response was not met for either cohort. However, pembrolizumab showed encouraging a ctivity in patients with undifferentiated pleomorphic sarcoma or dedi fferentiated liposarcoma. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2017; 18: 1061 –75
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1 –2 study. Lancet Oncol 2017; 18: 1061–75—In table S9 in the supplementary appendix of this Article, the composite remission in patients with ITD and D835 mutations should have been 7 (54%). The appendix has been corrected as of Nov 29, 2017. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2016; 17: 1637 –38
Guyton KZ, Loomis D, Grosse Y, et al, on behalf of the International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of pentachlorophenol and some related compounds. Lancet Oncol 2016; 17: 1637 –38—In this News piece (IARC monograph 117), one of the contributors has a potential conflict of interest that should have been declared. Warren Foster (a member of the Monograph Working Group) has previously contributed to the literature on endocrine disruption, for which he was compensated by Exponent through funds provided by the American Chemistry Council. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Correspondence] Go, no-go decision making for phase 3 clinical trials: ACT IV revisited – Authors' reply
We appreciate not only the interest of H Ian Robins and colleagues in the ACT IV trial,1 but also the thoughtful commentary by Elizbeth R Gerstner. From the perspective of several years' additional experience with clinical trial conduct in newly diagnosed glioblastoma relative to the time when ACT IV was designed, we feel that the failure to adequately estimate efficacy with a new treatment based on historical controls (even when matched for eligibility) provides a good lesson to be learned. (Source: The Lancet Oncology)
Source: The Lancet Oncology - November 30, 2017 Category: Cancer & Oncology Authors: Michael Weller, Nicholas Butowski, David D Tran, Lawrence D Recht, Michael Lim, Hal Hirte, Lynn Ashby, Laszlo Mechtler, Samuel A Goldlust, Fabio Iwamoto, Jan Drappatz, Donald M O'Rourke, Mark Wong, Mark G Hamilton, Gaetano Finocchiaro, James Perry, Wolfga Tags: Correspondence Source Type: research
